Department of Clinical Medicine, University of Insubria, UO Medicina I, Ospedale di Circolo, Varese, Italy.
Hematol Oncol Clin North Am. 2010 Aug;24(4):727-37, viii-ix. doi: 10.1016/j.hoc.2010.05.006.
Several new oral drugs that selectively and directly inhibit factor Xa seem promising alternatives to existing antithrombotic drugs. These drugs have a convenient route of administration, can be given in fixed doses, and do not require coagulation monitoring. Favorable results of clinical trials support their potential to change current practice. Translation into daily clinical practice may take some time; clinical studies over the next months and years will reveal the impact of rivaroxaban and other compounds in development. The aim of this review is to provide an overview of the more advanced oral, direct factor Xa inhibitors and to briefly describe the results of the completed studies.
几种新型的、选择性且直接抑制因子 Xa 的口服药物，似乎是现有抗血栓药物的理想替代品。这些药物给药途径方便、可固定剂量给药、且无需凝血监测。临床试验的良好结果支持了它们改变现有治疗方法的潜力。但要将这些成果转化为日常临床实践可能还需要一段时间；未来数月和数年的临床研究将揭示利伐沙班和其他在研药物的影响。本文旨在综述较为先进的口服直接因子 Xa 抑制剂，并简述已完成的研究结果。
